Mallinckrodt Pharma IP Trading D.a.c.

Fibriant B.v.

Mallinckrodt Oharma IP Trading D.a.c.

Joseph Grimbergen

Jacob Koopman

Abraham Bout

Miranda Weggeman

The present invention relates to compositions comprising fibrinogen gamma prime variants for use in the treatment or prevention of an infection and methods of administering the composition. The fibrinogen gamma prime variants in the composition comprise at least one fibrinogen gamma prime polypeptide chain. The compositions for use according to the invention may also comprise other fibrinogen variants. Compositions comprising fibrinogen gamma prime variants according to the invention improve survival time after infection up to more than 200 percent compared to WT fibrinogen. They may be used both therapeutically and prophylactically.

Therapeutic uses of fibrinogen gamma prime variants

The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.

Recombinant fibrinogen

The present invention relates to fibrinogen preparations enriched in &#x3b1;-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of &#x3b1;-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by &#x3b1;-extended fibrinogen are improved. In addition, plasmin-mediated degradation of &#x3b1;-extended fibrinogen is reduced as compared to plasma derived fibrinogen.

Growing community of inventors

Lisse, Netherlands

Joseph Grimbergen